Affibody AB
https://www.affibody.se/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Affibody AB
Finance Watch: Billions In And Billions Out In Venture Capital Fundraising
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
J&J Seeks Command Position In FcRn Space With Momenta Buyout
J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Sweden’s Affibody Inks Inmagene China R&D Pact
Swedish biotech Affibody hopes an R&D alliance with China-based Inmagene Biopharmaceuticals will speed development of its lead compound for auto-immune diseases.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Biotechnology
- Large Molecule